Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and ...
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to e...
Under the terms of the option agreement, Advancium paid Aileron a non-refundable fee for the exclusive option to acquire ALRN-6...
First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating lo...
Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-i...
Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate o...
